Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05852223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab in High-risk Thyroid Cancer

Study acronym: NePenThe
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2026 to Nov 2026
    • Study completion date: Dec 2027 to Nov 2026
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2024 to Dec 20, 2024
    • Site details revised
    v4
  3. Start date: Apr 2024 to Oct 2024
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2023 to Apr 2024
    • Primary endpoints: 1 to 2
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
Trial Details
NCT Number NCT05852223
Lead Sponsor Istituti Clinici Scientifici Maugeri SpA
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Differentiated Thyroid Cancer
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov